Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients-Reference-Cited by-同舟云学术

Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients

Published:2011 Issue:7 Volume:16 Page:951-957
ISSN:1359-6535
Container-title:Antiviral Therapy
language:
Short-container-title:Antivir Ther

Author:

Ruiz-Camps Isabel, ,Len Oscar,de la Cámara Rafael,Gurguí Mercedes,Martino Rodrigo,Jarque Isidro,Barrenetxea Cristina,Díaz de Heredia Cristina,Batlle Montserrat,Rovira Montserrat,de la Torre Julián,Torres Antonio,Aguilar Manuela,Espigado Ildefonso,Martín-Dávila Pilar,Bou German,Borrell Nuria,Aguado Jose Maria,Pahissa Albert

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants);Annals of Transplantation;2024-03-15

2. Oral Versus Intravenous Anti-CMV Preemptive Strategies in Allogeneic Stem Cell Transplant Patients with CMV Reactivation: Experience from the National Center of Bone Marrow Transplantation, Tunis, Tunisia;OBM Transplantation;2023-09-12

3. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants;International Journal of Antimicrobial Agents;2023-08

4. Research Progress on Predisposing Factors and Prevention of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation;Advances in Clinical Medicine;2023

5. How I Prevent Viral Reactivation in High-risk Patients;Blood;2022-12-09